{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:11:39Z","timestamp":1781946699134,"version":"3.54.5"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T00:00:00Z","timestamp":1539302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2018.10.012","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T20:54:34Z","timestamp":1541796874000},"page":"A73-A76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S1","title":["Global characteristics of the rabies biologics market in 2017"],"prefix":"10.1016","volume":"37","author":[{"given":"Annette","family":"Ives","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Dieuzy-Labaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6777-5298","authenticated-orcid":false,"given":"Bernadette","family":"Abela-Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.10.012_b0005","unstructured":"WHO. WHO Fact Sheet on Rabies; 2017, Available from: <http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/rabies> [01 September 2018]."},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.012_b0010","doi-asserted-by":"crossref","first-page":"e0003709","DOI":"10.1371\/journal.pntd.0003709","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.10.012_b0015","unstructured":"WHO. Zero by 30: the global strategic plan to end human deaths from dog-mediated rabies by 2030; 2018, Available from: <http:\/\/www.who.int\/rabies\/resources\/9789241513838\/en\/>."},{"key":"10.1016\/j.vaccine.2018.10.012_b0020","first-page":"93","article-title":"Rabies vaccines: WHO position paper \u2013 April 2018","volume":"16","author":"WHO","year":"2018","journal-title":"Wkly Epidemiol Rec, 2018"},{"issue":"9","key":"10.1016\/j.vaccine.2018.10.012_b0025","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2471\/BLT.16.183012","article-title":"Rabies vaccine stockpile: fixing the supply chain","volume":"94","author":"Abela-Ridder","year":"2016","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2018.10.012_b0030","unstructured":"GAVI. Report to the Board, 6-7 June 2018: Vaccine Investment Strategy: Short List; 2018 01 September 2018; Available from: <https:\/\/www.gavi.org\/about\/governance\/gavi-board\/minutes\/2018\/6-june\/minutes\/07---vaccine-investment-strategy---short-list\/>."},{"key":"10.1016\/j.vaccine.2018.10.012_b0035","unstructured":"GAVI. Vaccine investment strategy; 2018 [cited 2018 01 September 2018]; Available from: <https:\/\/www.gavi.org\/about\/strategy\/vaccine-investment-strategy\/>."},{"key":"10.1016\/j.vaccine.2018.10.012_b0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fvets.2017.00009","article-title":"elimination of dog-mediated human rabies deaths by 2030: needs assessment and alternatives for progress based on dog vaccination","volume":"4","author":"Wallace","year":"2017","journal-title":"Front Vet Sci"},{"key":"10.1016\/j.vaccine.2018.10.012_b0045","unstructured":"WHO. Getting started with vaccine vial monitors; 2002 03 September 2018, Available from: <http:\/\/apps.who.int\/iris\/bitstream\/10665\/67806\/1\/WHO_V-B_02.35_eng.pdf?ua=1>."},{"key":"10.1016\/j.vaccine.2018.10.012_b0050","unstructured":"WHO. Background paper: proposed revision of the policy on rabies vaccines and rabies immunoglobulins; 2017 11 December 2017, Available from: <http:\/\/www.who.int\/immunization\/sage\/meetings\/2017\/october\/1_Background_paper_WG_RABIES_final.pdf>."},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.012_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tmaid.2011.12.005","article-title":"Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure","volume":"10","author":"Warrell","year":"2012","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.012_b0060","doi-asserted-by":"crossref","first-page":"184","DOI":"10.12688\/f1000research.10416.1","article-title":"Lyssaviruses and rabies: current conundrums, concerns, contradictions and controversies","volume":"6","author":"Rupprecht","year":"2017","journal-title":"F1000Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T18:30:32Z","timestamp":1569522632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18313641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":12,"alternative-id":["S0264410X18313641"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.012","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global characteristics of the rabies biologics market in 2017","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}